NeuroBo Pharmaceuticals(NRBO) - 2022 Q1 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Form 10-Q Commission file number 001-37809 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 NeuroBo Pharmaceuticals, Inc. OR (Exact name of Registrant as specified in its charter) Delaware 47-2389984 (State or ot ...